darapladib

DRUG10 trials

Conditions

AtherosclerosisCoronary Heart DiseaseEndothelial DysfunctionRetinopathy, Diabetic

Phase 1

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

CompletedNCT00411073

GlaxoSmithKlineAtherosclerosis

Start: 2006-12-31Target: 72Updated: 2016-10-28

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

CompletedNCT00743860

GlaxoSmithKlineAtherosclerosis

Start: 2008-09-30End: 2008-12-31Updated: 2016-11-16

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

CompletedNCT01154114

GlaxoSmithKlineAtherosclerosis

Start: 2010-07-01End: 2010-10-15Updated: 2017-07-26

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

CompletedNCT01852565

GlaxoSmithKlineAtherosclerosis

Start: 2013-05-14End: 2013-09-30Updated: 2017-07-13

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

CompletedNCT01873339

GlaxoSmithKlineAtherosclerosis

Start: 2013-06-19End: 2013-09-12Updated: 2017-05-15

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT02058641

GlaxoSmithKlineAtherosclerosis

Start: 2014-02-26End: 2014-08-18Updated: 2017-05-15

Phase 2

A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

CompletedNCT01506895

GlaxoSmithKlineRetinopathy, Diabetic

Start: 2012-02-29End: 2013-02-28Updated: 2016-11-21

Phase 3

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

CompletedNCT00799903

GlaxoSmithKlineAtherosclerosis

Start: 2008-12-01End: 2013-10-17Updated: 2017-08-10

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

CompletedNCT01067339

Mayo ClinicEndothelial Dysfunction

Start: 2010-02-04End: 2015-11-30Updated: 2017-04-18

Unknown Phase

SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

CompletedNCT01636271

GlaxoSmithKlineCoronary Heart Disease

Start: 2011-10-31End: 2014-04-30Updated: 2014-11-03

Frontiers in Cardiovascular Medicine2024-09-265 citations

Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

Journal of the American Heart Association2022-07-1526 citations

Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy

Journal of the American Heart Association2022-01-2171 citations

Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events

Diabetologia2021-09-2516 citations

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

PLoS Medicine2021-01-13119 citations

Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.

2020-05-0751 citations

Chronic inhibition of lipoprotein-associated phospholipase A<sub>2</sub> does not improve coronary endothelial function: A prospective, randomized-controlled trial.

2018-02-018 citations

Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

Journal of the American Heart Association2017-10-11269 citations

Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

Journal of the American Heart Association2017-09-1534 citations

Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease

Journal of the American Heart Association2017-08-0211 citations

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.

2017-08-0199 citations

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.

2017-07-1723 citations

Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease

Clinical Chemistry2016-11-04126 citations

Lipoprotein‐Associated Phospholipase A <sub>2</sub> Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

Journal of the American Heart Association2016-06-1360 citations

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.

2016-02-25298 citations

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial

PLoS ONE2015-10-146 citations

A 24‐week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease

Alzheimer s & Dementia Translational Research & Clinical Interventions2015-06-2950 citations

STABILITY: Darapladib and Lp-PLA2 Levels in Treatment of Atherosclerosis

MD Conference Express2014-10-01

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

New England Journal of Medicine2014-03-30566 citations

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

PLoS ONE2014-01-2722 citations

darapladib

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Unknown Phase

Related Papers